Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin
- PMID: 17853313
- DOI: 10.1080/09546630600919993
Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin
Abstract
Pegylated liposomal doxorubicin (PLD) is usually used in disseminated HIV-related Kaposi's sarcoma (KS). It is the first-line treatment or second-line therapy in patients who do not tolerate or do not respond to polychemotherapy since 1995, when it was approved by the FDA. We report two cases of disseminated classic KS not associated with immunosuppression in which HHV-8 infection was demonstrated. They showed an excellent response to PLD, with good tolerance and an absence of side effects.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources